SKYX Platforms risk analysis
Want to see SKYX full AI Analyst Report?
SKYX Platforms (SKYX) Risk Analysis
Risk Overview Q3, 2026
Source: the company's latest filing for the period ended Sep 30, 2026, filed Nov 12, 2026
Risk Change Over Time
- Share Price & Shareholder Rights - Risk 1Sales of a substantial number of shares of our common stock in the public market, including shares issued in connection with the Merger, could cause our stock price to fall.
Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur, could significantly reduce the market price of our common stock. In connection with the Merger, we issued approximately 25 million shares of common stock. We are unable to predict the effect, if any, that sales of shares, or the availability of shares for sale, will have on the market price of our common stock. Certain of the shares issued in connection with the Merger are subject to lock-up restrictions, but upon the expiration of such restrictions, the holders of those shares will be able to sell them in the public market, subject to applicable securities laws. The sale of these shares, or the possibility that these sales may occur, also may make it more difficult for us to raise additional capital by selling equity securities in the future, at a time and price that we deem appropriate.
Risk Highlights Q3, 2026
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 71
- Share Price & Shareholder Rights - Risk 1ChangedSales of a substantial number of shares of our common stock in the public market, including shares issued in connection with the Merger, could cause our stock price to fall.
Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur, could significantly reduce the market price of our common stock. In connection with the Merger, we issued approximately 25 million shares of common stock. We are unable to predict the effect, if any, that sales of shares, or the availability of shares for sale, will have on the market price of our common stock. Certain of the shares issued in connection with the Merger are subject to lock-up restrictions, but upon the expiration of such restrictions, the holders of those shares will be able to sell them in the public market, subject to applicable securities laws. The sale of these shares, or the possibility that these sales may occur, also may make it more difficult for us to raise additional capital by selling equity securities in the future, at a time and price that we deem appropriate.
- Share Price & Shareholder Rights - Risk 2AddedWe issued a large number of shares of common stock in connection with the Merger, which resulted in substantial dilution to our existing stockholders, and our stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they experienced.
Our issuance of the shares pursuant to the merger with Deako resulted in substantial dilution of our existing stockholders' ownership interests. The share issuance may also have an adverse impact on our net income per share in fiscal periods that include and follow the closing of the Merger. If we are unable to realize the strategic and financial benefits currently anticipated from the Merger, our stockholders will have experienced substantial dilution of their ownership interest without receiving commensurate benefit.
- Share Price & Shareholder Rights - Risk 3AddedWe are currently not in compliance with Nasdaq's board independence and audit committee composition requirements, and if we fail to regain compliance within the applicable cure period, our common stock could be delisted from Nasdaq.
Our common stock is listed on Nasdaq, and to maintain this listing we must satisfy Nasdaq's continued listing requirements, including its corporate governance requirements. On September 26, 2026, Efrat L. Greenstein Brayer, an independent member of our board of directors who served on our audit committee and compensation committee and chaired our nominating and corporate governance committee, passed away. As a result, we are no longer in compliance with Nasdaq Listing Rule 5605(b)(1), which requires that a majority of our board of directors consist of independent directors, or with Nasdaq Listing Rule 5605(c)(2)(A), which requires that our audit committee consist of at least three members. We notified Nasdaq of these deficiencies on September 28, 2026. On September 30, 2026, we received a letter from Nasdaq confirming that, under Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4)(B), we are entitled to a cure period to regain compliance. The cure period expires on the earlier of our next annual meeting of stockholders or September 26, 2027; provided, however, if our next annual meeting of stockholders is held before March 25, 2027, then we must evidence compliance no later than March 25, 2027. We intend to take sufficient actions to regain compliance with the foregoing Nasdaq governance requirements within the applicable cure period. However, we cannot assure you that we will be able to identify and appoint a suitable independent director candidate, or otherwise regain compliance with these requirements, within the cure period or at all. If we do not regain compliance in time, Nasdaq will notify us that our common stock is subject to delisting. We could then appeal that determination to a Nasdaq Hearings Panel, but we cannot assure you that any appeal would succeed. The delisting of our common stock could significantly reduce its liquidity and market price, adversely affect our ability to raise capital on acceptable terms or at all, and harm our reputation with customers, suppliers, employees and investors.
- Share Price & Shareholder Rights - Risk 4Anti-takeover provisions in our charter documents and under Florida law could discourage, delay or prevent a change in control of us and may affect the trading price of our common stock.
As a Florida corporation, we are subject to certain provisions of the Florida Business Corporation Act that have anti-takeover effects and may inhibit a non-negotiated merger or other business combination. Our articles of incorporation and bylaws also contain other provisions which could have anti-takeover effects. These provisions include, without limitation, the authority of our board of directors to designate and issue shares of preferred stock, including to fix the relative rights and preferences of the preferred stock without the need for any stockholder vote or approval; the requirement of a majority stockholder vote to remove directors from office or, if for cause, by a majority of the board of directors; and limitations on who may call special meetings of stockholders.
- Share Price & Shareholder Rights - Risk 5We are a smaller reporting company, and the reduced reporting requirements applicable to smaller reporting companies may make our common stock less attractive to investors.
We currently qualify as a "smaller reporting company," which allows us to take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not smaller reporting companies, including reduced disclosure obligations regarding executive compensation in this Form 10-K and our periodic reports and proxy statements. Decreased disclosures in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze the results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these reduced reporting requirements. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile.
- Share Price & Shareholder Rights - Risk 6Our executive officers, directors, principal stockholders, and their affiliates exercise considerable influence over us, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control. In addition, our outstanding convertible preferred stock has voting rights, which reduce the relative voting power of holders of our common stock.
Our executive officers, directors, 5% holders of our common stock and their affiliates beneficially own, in the aggregate, approximately 23.6% of our outstanding common stock, or 23.6% of our total voting power, as of March 18, 2026. In addition, holders of our Series A Preferred Stock, Series A-1 Preferred Stock and Series A-2 Preferred Stock, which includes certain of our officers, are entitled to vote on an as-converted basis, together with holders of our common stock on all matters submitted to a vote of the holders of our common stock. As a result, the issuance of such preferred stock effectively reduced the relative voting power of the holders of our common stock. The holders of such preferred stock have approximately 7.1% of the Company's total voting power as of March 18, 2026. These stockholders, if they act together, will be able to influence our management and affairs and the outcome of matters submitted to our stockholders for approval, including the election of directors and any merger, consolidation or sale of all or substantially all of our assets. These stockholders may have interests that are different from those of other investors, and the concentration of voting power among these stockholders may have an adverse effect on the price of our common stock. In addition, this concentration of ownership might adversely affect the market price of our common stock by: - delaying, deferring, or preventing a change of control of us; - impeding a merger, consolidation, takeover or other business combination involving us; or - discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.
- Share Price & Shareholder Rights - Risk 7If securities analysts do not publish research or reports about our business, or if they publish negative evaluations of our stock, the price of our stock could decline.
The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.
- Share Price & Shareholder Rights - Risk 8The outstanding preferred stock has rights, preferences and privileges that will not be held by, and will be preferential to, the rights of holders of our common stock, which could adversely affect the liquidity and financial condition of the Company, and may result in the interests of the holders of our outstanding preferred stock differing from those of the holders of our common stock.
The Series A Preferred Stock, Series A-1 Preferred Stock, and Series A-2 Preferred Stock rank on parity with each other with respect to liquidation preferences. Upon any dissolution, liquidation or winding up, whether voluntary or involuntary, holders of such preferred stock will be entitled to receive distributions out of the Company's assets in an amount per share equal to $25.00 plus all accrued and unpaid dividends, whether capital or surplus, before any distributions shall be made on any shares of common stock. These dividend obligations to the holders of preferred stock could limit the Company's ability to obtain additional financing, which could have an adverse effect on its financial condition. The preferential rights described above could also result in divergent interests between the holders of shares of preferred stock and the holders of our common stock.
- Share Price & Shareholder Rights - Risk 9The conversion of outstanding convertible notes or preferred stock into shares of common stock could materially dilute our stockholders.
As of March 18, 2026, we had $18.2 million aggregate principal amount of convertible notes outstanding, convertible into shares of our common stock at a weighted average conversion rate of $1.28 and $13.8 million invested in our shares of Preferred Series A, A-1 and A-2, convertible at a weighted average rate of $1.25 per share. The effective conversion price of the notes or preferred stock or exercise price of the warrants may be less than the market price of our common stock at the time of conversion or exercise If the entire principal amount of all the outstanding convertible notes and preferred shares is converted into shares of common stock, we would be required to issue an aggregate 25,679,364 shares of common stock. If we issue any or all of these shares, the ownership of our stockholders will be diluted.
- Share Price & Shareholder Rights - Risk 10The price of our common stock may be volatile and fluctuate substantially.
Our stock price has been, and is likely to continue to be, volatile and subject to wide fluctuations in response to numerous factors, some of which we cannot control. The stock market has experienced extreme volatility that has often been unrelated to the operating performance of companies. The market price for our common stock may be influenced by many factors, including, in addition to the factors discussed in this "Risk Factors" section and elsewhere in this Form 10-K, the following: - our ability to successfully launch, and gain market acceptance of, our smart products and technologies; - our reliance on product distribution arrangements with third parties; - developments or disputes concerning patent applications, issued patents or other proprietary rights; - the recruitment or departure of key personnel; - the level of expenses related to our research and development, marketing efforts, strategic initiatives, or other areas; - actual or anticipated changes in governmental regulation, including taxation and tariff policies; - actual or anticipated changes in estimates as to financial results or recommendations by securities analysts; - variations in our financial results or those of companies that are perceived to be similar to us; - market conditions in the lighting, home decor and smart home sectors; - conditions in the financial markets in general or changes in general economic conditions; and - novel and unforeseen market forces and trading strategies. In addition, due to one or more of the foregoing factors in one or more future quarters, our results of operations may fall below the expectations of securities analysts and investors. In the event any of the foregoing factors occur, the market price of our common stock could be highly volatile and may materially decline. Further, in the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs by defending the lawsuit. Such a lawsuit could also divert the time and attention of our management from our business, which could significantly harm our profitability and reputation.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.

